Female sexual dysfunction: Focus on low desire

Obstetrics and Gynecology

Volumn 125, Issue 2, 2015, Pages 477-486

  Kingsberg, Sheryl A ^a   Woodard, Terri ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; OSPEMIFENE;

ARTICLE; DEPRESSION; DRUG EFFICACY; DSM-5; DYSPAREUNIA; ESTROGEN THERAPY; FEMALE; FEMALE SEXUAL DYSFUNCTION; HUMAN; HYPOACTIVE SEXUAL DESIRE DISORDER; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; SCREENING; SEXUAL BEHAVIOR; SEXUAL EDUCATION; SEXUAL FUNCTION; VAGINA ATROPHY; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

FEMALE; HUMANS; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

EID: 84922475172     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000620     Document Type: Article

References (61)

1. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281: 537-44
2. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 2008; 112: 970-8
3. American Psychiatric Association, American Psychiatric Association, DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, DC: American Psychiatric Association; 2013
4. American Psychiatric Association, American Psychiatric Association. Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed. Washington, DC: American Psychiatric Association; 2000
5. Kingsberg SA, Rezaee RL. Hypoactive sexual desire in women. Menopause 2013; 20: 1284-300
6. Leiblum SR, Koochaki PE, Rodenberg CA, Barton IP, Rosen RC. Hypoactive sexual desire disorder in postmenopausal women: US results from the Women's International Study of Health and Sexuality (WISHeS). Menopause 2006; 13: 46-56
7. Biddle AK, West SL, D'Aloisio AA, Wheeler SB, Borisov NN, Thorp J. Hypoactive sexual desire disorder in postmenopausal women: quality of life and health burden. Value Health 2009; 12: 763-72
8. Basson R. Human sex-response cycles. J Sex Marital Ther 2001; 27: 33-43
9. Binik YM, Brotto LA, Graham CA, Segraves RT. Response of the DSM-V Sexual Dysfunctions subworkgroup to commentaries published in JSM. J Sex Med 2010; 7: 2382-7
10. ter Kuile MM, Brauer M, Laan E. The Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS): psychometric properties within a Dutch population. J Sex Marital Ther 2006; 32: 289-304
11. West SL, D'Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM. Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. Arch Intern Med 2008; 168: 1441-9
12. Rosen RC, Connor MK, Miyasato G, Link C, Shifren JL, Fisher WA, et al. Sexual desire problems in women seeking healthcare: a novel study design for ascertaining prevalence of hypoactive sexual desire disorder in clinic-based samples of US women. J Womens Health (Larchmt) 2012; 21: 505-15
13. Engel GL. The need for a new medical model: a challenge for biomedicine. Science 1977; 196: 129-36
14. Basson R, Schultz WW. Sexual sequelae of general medical disorders. Lancet 2007; 369: 409-24
15. Finger WW, Lund M, Slagle MA. Medications that may contribute to sexual disorders A guide to assessment and treatment in family practice. J Fam Pract 1997; 44: 33-43
16. Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 2008; 15: 661-6
17. Dennerstein L, Lehert P, Burger H, Dudley E. Factors affecting sexual functioning of women in the mid-life years. Climacteric 1999; 2: 254-62
18. Brotto LA, Bitzer J, Laan E, Leiblum S, Luria M. Women's sexual desire and arousal disorders. J Sex Med 2010; 7: 586-614
19. Rubio-Aurioles E, Kim ED, Rosen RC, Porst H, Burns P, Zeigler H, et al. Impact on erectile function and sexual quality of life of couples: a double-blind, randomized, placebo-controlled trial of tadalafil taken once daily. J Sex Med 2009; 6: 1314-23
20. Rosen RC, Connor MK, Maserejian NN. The HSDD registry for women: a novel patient registry for women with generalized acquired hypoactive sexual desire disorder. J Sex Med 2010; 7: 1747-56
21. Shifren JL, Johannes CB, Monz BU, Russo PA, Bennett L, Rosen R. Help-seeking behavior of women with self-reported distressing sexual problems. J Womens Health (Larchmt) 2009; 18: 461-8
22. Berman L, Berman J, Felder S, Pollets D, Chhabra S, Miles M, et al. Seeking help for sexual function complaints: what gynecologists need to know about the female patient's experience. Fertil Steril 2003; 79: 572-6
23. Buster JE. Managing female sexual dysfunction. Fertil Steril 2013; 100: 905-15
24. Hughes AK. Mid-To-late-life women and sexual health: communication with health care providers. Fam Med 2013; 45: 252-6
25. Clayton AH, Goldfischer ER, Goldstein I, Derogatis L, Lewis-D'Agostino DJ, Pyke R. Validation of the decreased sexual desire screener (DSDS): a brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD). J Sex Med 2009; 6: 730-8
26. Wallwiener CW, Wallwiener LM, Seeger H, Muck AO, Bitzer J, Wallwiener M. Prevalence of sexual dysfunction and impact of contraception in female German medical students. J Sex Med 2010; 7: 2139-48
27. Bitzer J, Tschudin S, Meier-Burgoa J, Armbruster U, Schwendke A. Effects on the quality of life of a new oral contraceptive containing 30 mcg EE and 3 mg drospirenone (Yasmin) [in German]. Praxis (Bern 1994) 2003; 92: 1177-84
28. Burrows LJ, Basha M, Goldstein AT. The effects of hormonal contraceptives on female sexuality: a review. J Sex Med 2012; 9: 2213-23
29. Pastor Z, Holla K, Chmel R. The influence of combined oral contraceptives on female sexual desire: a systematic review. Eur J Contracept Reprod Health Care 2013; 18: 27-43
30. Althof SE, Rosen RC, Perelman MA, Rubio-Aurioles E. Standard operating procedures for taking a sexual history. J Sex Med 2013; 10: 26-35
31. Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA 2005; 294: 91-6
32. Santoro N, Torrens J, Crawford S, Allsworth JE, Finkelstein JS, Gold EB, et al. Correlates of circulating androgens in mid-life women: the study of women's health across the nation. J Clin Endocrinol Metab 2005; 90: 4836-45
33. Guay AT, Jacobson J. Decreased free testosterone and dehydroepiandrosterone-sulfate (DHEA-S) levels in women with decreased libido. J Sex Marital Ther 2002; 28(suppl 1): 129-42
34. Talakoub L, Munarriz R, Hoag L, Gioia M, Flaherty E, Goldstein I. Epidemiological characteristics of 250 women with sexual dysfunction who presented for initial evaluation. J Sex Marital Ther 2002; 28(suppl 1): 217-24
35. Aanon JS. Behavioral treatment of sexual problems: brief therapy. Hagerstown (MD): Harper and Row; 1976
36. Trudela GMA, Ravartb M, Aubinb S, Turgeonb L, Fortierb P. The effect of a cognitive-behavioral group treatment program on hypoactive sexual desire in women. Sex Relat Ther 2001; 16: 145-64
37. Hawton K, Catalan J, Martin P, Fagg J. Long-Term outcome of sex therapy. Behav Res Ther 1986; 24: 665-75
38. Brotto LA, Basson R, Luria M A mindfulness-based group psychoeducational intervention targeting sexual arousal disorder in women. J Sex Med 2008; 5: 1646-59
39. Günzler C, Berner MM. Efficacy of psychosocial interventions in men and women with sexual dysfunctions-A systematic review of controlled clinical trials: part 2-The efficacy of psychosocial interventions for female sexual dysfunction. J SexMed 2012; 9: 3108-25
40. Bradford A. Inhibited sexual desire in women. In: Grossman LR, Walfish S, editors. Translating psychological research into practice. New York (NY): Springer; 2013: p. 515-8
41. Brotto LA, Erskine Y, Carey M, Ehlen T, Finlayson S, Heywood M, et al A brief mindfulness-based cognitive behavioral intervention improves sexual functioning versus wait-list control in women treated for gynecologic cancer. Gynecol Oncol 2012; 125: 320-5
42. Cui Y, Zong H, Yan H, Li N, Zhang Y. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-Analysis. J Sex Med 2014; 11: 487-97
43. Goldstein SR, Bachmann GA, Koninckx PR, Lin VH, Portman DJ, Ylikorkala O, et al. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric 2014; 17: 173-82
44. Davis SR, Braunstein GD. Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. J Sex Med 2012; 9: 1134-48
45. Snabes MC, Simes SM. Approved hormonal treatments for HSDD: an unmet medical need. J Sex Med 2009; 6: 1846-9
46. Somboonporn W, Davis S, Seif MW, Bell R. Testosterone for peri-And postmenopausal women. The Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD004509. DOI: 10.1002/14651858.CD004509.pub2
47. Braunstein GD. Safety of testosterone treatment in postmenopausal women. Fertil Steril 2007; 88: 1-17
48. Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008; 359: 2005-17
49. Female sexual dysfunction. Practice Bulletin No. 119. American College of Obstetricians and Gynecologists. Obstet Gynecol 2011; 117: 996-1007
50. Nachtigall L, Casson P, Lucas J, Schofield V, Melson C, Simon JA. Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecol Endocrinol 2011; 27: 39-48
51. Brand JS, van der Schouw YT. Testosterone, SHBG and cardiovascular health in postmenopausal women. Int J Impot Res 2010; 22: 91-104
52. Laughlin GA, Goodell V, Barrett-Connor E. Extremes of endogenous testosterone are associated with increased risk of incident coronary events in older women. J Clin Endocrinol Metab 2010; 95: 740-7
53. Davis SR. Cardiovascular and cancer safety of testosterone in women. Curr Opin Endocrinol Diabetes Obes 2011; 18: 198-203
54. Ness RB, Albano JD, McTiernan A, Cauley JA. Influence of estrogen plus testosterone supplementation on breast cancer. Arch Intern Med 2009; 169: 41-6
55. White WB, Grady D, Giudice LC, Berry SM, Zborowski J, Snabes MC A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder. Am Heart J 2012; 163: 27-32
56. Segraves RT, Croft H, Kavoussi R, Ascher JA, Batey SR, Foster VJ, et al. Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women. J Sex Marital Ther 2001; 27: 303-16
57. Safarinejad MR, Hosseini SY, Asgari MA, Dadkhah F, Taghva A A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women. BJU Int 2010; 106: 832-9
58. Safarinejad MR. Reversal of SSRI-induced female sexual dysfunction by adjunctive bupropion in menstruating women: a double-blind, placebo-controlled and randomized study. J Psychopharmacol 2011; 25: 370-8
59. Poels S, Bloemers J, van Rooij K, Goldstein I, Gerritsen J, van Ham D, et al. Toward personalized sexual medicine (part 2): testosterone combined with a PDE5 inhibitor increases sexual satisfaction in women with HSDD and FSAD, and a low sensitive system for sexual cues. J Sex Med 2013; 10: 810-23
60. van Rooij K, Poels S, Bloemers J, Goldstein I, Gerritsen J, van Ham D, et al. Toward personalized sexual medicine (part 3): testosterone combined with a Serotonin1A receptor agonist increases sexual satisfaction in women with HSDD and FSAD, and dysfunctional activation of sexual inhibitory mechanisms. J Sex Med 2013; 10: 824-37
61. Portman DJ, Edelson J, Jordan R, Clayton A, Krychman ML. Bremelanotide for hypoactive sexual desire disorder: analyses from a phase 2B dose-ranging study. Obstet Gynecol 2014; 123 (suppl 1): 31S.